SRPT Q2 2021 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$164M+19.5% YoY

Gross Profit

$145M88.1% margin

Operating Income

-$168M-102.1% margin

Net Income

-$81M-49.6% margin

EPS (Diluted)

$-1.02

QoQ Revenue Growth

+11.7%

Cash Flow

Operating Cash Flow

-$109M

Free Cash Flow

-$115M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$2.8B

Total Liabilities

$2.3B

Stockholders' Equity

$485M

Cash & Equivalents

$1.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$164M	$137M	+19.5%
Gross Profit	$145M	$124M	+16.6%
Operating Income	-$168M	-$138M	-21.1%
Net Income	-$81M	-$151M	+46.0%

Revenue Segments

E X O N D Y S Fifty One

$112M79%

V Y O N D Y S Fifty Three

$22M16%

A M O N D Y S Fourty Five

$7M5%